Everads Therapy wins retina commercialization option deal

Moshe Weinstein  / Photo: PR
Moshe Weinstein / Photo: PR

The Israeli company will potentially receive an upfront fee and payments for milestones from an unnamed drug developer.

While the coronavirus is raging, people are still contracting other diseases, and medical companies are still trying to heal them. Everads Therapy, founded on the basis of in invention by ophthalmologist Dr. Ygal Rotenstreich, head of the Electrophysiology Clinic and Retinal Research Laboratory at the Goldschleger Eye Institute of Sheba Medical Center, has signed a commercialization option agreement for its device for injecting drugs into the back part of the eye via the suprachoroidal space. The name of the other company in the agreement, which markets drugs for ophthalmological diseases with a potential market in the billions of dollars, was not disclosed, nor was the price of the deal.

Everads will receive an advance and payments for milestones. If the product is integrated with the other company's drug and the cocktail reaches the market, Everads will receive a proportion of the other company's revenue from the drug. The other company will pay the cost of developing the product. Under the agreement, the other company received exclusivity for a number of uses for a syringe, while Everads is continuing its development independently for other indications.

Everads’ founders are Rotenstreich; Dr. Ifat Sher, head of the restorative retinal research laboratory at Sheba Medical Center; and medical devices company DALI, which develops solutions for injecting drugs. Dali has already brought a syringe to a deal with a large company for use with a bestselling drug. Everads COO Hagay Drori, a former product manager at DALI, says, "The company founders came to us in order to cooperate with us in development of the syringe, and as part of this cooperation, I eventually switched to working with them."

Drugs targeting the retina can help treat various retinal diseases, including dry AMD, wet AMD, and other diabetic degenerative retinal diseases. In order to reach the retina, current drugs are commonly injected into the globe (the vitreous) of the eye, or, sub-retinally in the rear part of the eye. When they are injected through the front part of the eye, the full amount does not reach the targeted tissue, and sometimes causes damage to other tissues.

Everads executive chairman Moshe Weinstein says, "Subretinal administration is a complicated matter and requires surgery, and is often accompanied by significant safety risks. Suprachoroidal injection done via Everads’ device potentially alleviates these risks."

The device developed by Everads contains a sharp needle that is slightly inserted into the front part of the eye, where it is less dangerous to make injections. A blunt component is extended through the needle once inside the eye. When the blunt component is extended towards the rear part of the eye, it separates tissues, without penetrating them. This creates a channel from the middle of the eye, and the drug is injected through this channel. The channel is gradually closed by pressure within the eye. The process turns a complicated injection into the rear of the eye into a less complicated injection into the front of the eye. The blunt separator's circumference is less than one millimeter.

Weinstein says that Evards's main competitor is Clearside BIO, listed on Nasdaq with a $76 million market cap. The company has an agreement with Bausch & Lomb, one of the leading ophthalmological companies. Clearside's technology, however, differs slightly from that of Everads.

Everads was founded in 2017 in the RAD BioMed incubator, after obtaining a license from Sheba Medical Center's commercialization company.

Published by Globes, Israel business news - en.globes.co.il - on March 18, 2020

© Copyright of Globes Publisher Itonut (1983) Ltd. 2020

Moshe Weinstein  / Photo: PR
Moshe Weinstein / Photo: PR
Credit Card payment terminal credit: Seika Chujo Shutterstock Cyberattack again disrupts Israel's credit card payments

Check Point chief of staff Gil Messing: "These are the capabilities of a state actor. This does not necessarily mean Iran, but in the past Iranian entities have been behind such attacks.

CyberArk offices credit: Eyal Izhar CyberArk buys US co Zilla Security, reports strong Q4

CyberArk, which will pay $165 million for the US identity governance and administration company, has surpassed Teva to become Israel's second most valuable company.

mSphere credit: Mer Group Mer launches armored vehicle awareness protection system

mSphere's comprehensive monitoring eliminates blind spots, enhances detection capabilities, and enables crews to identify and respond to potential threats swiftly and accurately.

Mortgage taking credit: Shutterstock Steep fall in mortgage taking in Israel in January

Mortgage taking was down 50% from the preceding month but up 30% from January 2024, the Bank of Israel reports.

Shekel-dollar ASAP Creative Shekel rebounds against dollar

Bank Leumi: The possibility of further appreciation of the shekel, raises the question of whether portfolio owners with high exposure to foreign exchange have a reason to hedge their investment portfolio.

Amnon Shashua  credit: Eyal Izhar Shashua's Mentee Robotics unveils robot for manual work

MenteeBot V3.0 takes on lifting tasks that would typically be strenuous for human workers over extended periods.

New housing credit: Satenik Guzhanina Shutterstock 50% of housing deals in 2024 were developer loans

What made 2024 distinct was that 50% of deals involved special offers by contractors and developers for apartments not yet built, the Ministry of Finance reports.

Donald Trump  credit: Reuters/Brendan McDermid Trump administration reaffirms AI chip restrictions on Israel

Sources say the US will demand Israel passes regulations to prevent tech leakage to China and may even include removal of the restrictions as part of a multilateral Middle East agreement.

Accountant General Yali Rothenberg credit: Cadya Levy Israel raises $5b international bond

Accountant General: This is an important public offering that indicates the financial stability of the State of Israel and the high confidence of global investors in the Israeli economy.

Check Point Chairman Gil Shwed and CEO Nadav Zafrir credit: Check Point Check Point teams with Wiz to challenge Palo Alto

The veteran cybersecurity company has formed a strategic partnership with Israeli company Wiz to provide end-to-end cloud security.

Mobileye autonomous taxi  credit: Mobileye Mobileye to team with Lyft on Robotaxis in Dallas

Ridesharing giant Lyft CEO David Risher said that his company will launch the robotaxis in Dallas in 2026.

Voyantis founders credit: Guy Sidi Israeli predictive AI co Voyantis raises $41m

Voyantis combines predictive and prescriptive AI to eliminate guesswork traditionally involved in assessing a customer’s potential value.

Karin Eibschitz Segal. credit: Ohad Falik Intel Israel CEO named interim head of DCAI

Intel Israel CEO Karin Eibschitz Segal has been appointed Intel's interim head of Intel's data center and artificial intelligence, the third most important position at the US chipmaker.

Shekel v dollar  credit: Tali Bogdanovsky using Adobe Firefly Shekel weaker amid hostage release uncertainties

Bank Hapoalim: This is a correction, the shekel will continue to strengthen.

Avi Simhon, Bezalel Smotrich and Yogev Gradus credit: Yossi Cohen, Noam Moskovich/Knesset Spokesperson, Amit Shabi/Yediot Ahronot Israeli gov't mulls tax cuts as deficit narrows

National Economic Council chairman Prof. Avi Simhon: If we are convinced this is a continuing trend, the first tax I would reduce is cutting VAT back to 17%.

Elbit Systems president and CEO Bezhalel Makhlis credit: Assaf Shilo Israel Sun Prioritizing Israel creates problems for Elbit

Ministry of Defense demands to supply Israel first has meant overseas deliveries have been delayed, irking the Philippines in particular.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018